We easily recall many of our first experiences as they often signal important milestones in our lives. History duly records the first time of many things, such as the first steps on the moon, the first phone call ever made, the iconic story of the first cell phone call, etc. We may be witnessing another important “first.”
Recently, we talked about how our blood is awash with information about what’s happening in our bodies, and how that information might be tapped to glean medical insights. We cautioned that care must be exercised when determining which messages are important so as to avoid missed diagnoses or undergoing unnecessary and invasive treatments. Procedures for extracting medical insights from blood need to be thoroughly vetted in real people to determine the validity of the test in a clinical setting.
We are pleased to announce that the first significant use of our “protein-listening” SOMAscan® platform in a clinical setting has begun recruiting! In a recent press release, our UK collaborators proudly announced that the Leeds Centre for Personalised Medicine and Health enrolled the first person for a study involving 1000 patients. This study will assess how SomaLogic’s proteomic insights can guide a person to adopt lifestyle changes to ward off the onset of type 2 diabetes. Our Chief Medical officer, Steve Williams, MD, noted that this is the “first time in history” that a test involving 5,000 proteins will be used in preventative treatment.
We are excited to see the outcomes from this first clinical application of the SOMAscan platform insights. It could be the emphatic validation that proteomics uniquely provides the right information to identify the right treatment for the right patient at the right time. A true first for human health around the world, and one to remember.